Carfilzomib公司
来那度胺
医学
地塞米松
多发性骨髓瘤
肿瘤科
蛋白酶体抑制剂
内科学
药理学
作者
A. Keith Stewart,S. Vincent Rajkumar,Meletios Α. Dimopoulos,Tamás Masszi,Ivan Špıčka,Albert Oriol,Roman Hájek,Laura Rosiñol,David S. Siegel,Georgi Mihaylov,Vesselina Goranova‐Marinova,Péter Rajnics,Aleksandr Suvorov,Rubén Niesvizky,Andrzej Jakubowiak,Jesús F. San Miguel,Heinz Ludwig,Michael Wang,Vladimír Maisnar,Jiří Minařík
标识
DOI：10.1056/nejmoa1411321
摘要
Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and dexamethasone has shown efficacy in a phase 1 and 2 study in relapsed multiple myeloma.
科研通智能强力驱动
Strongly Powered by AbleSci AI
pluto
jenningseastera
平常的毛豆
忐忑的黑猫
qiao
科研小民工
午见千山
HEAUBOOK
森鹿
余味
bc
乐乐
CyrusSo524
iNk
827584450
桐桐
cdercder
归尘
竹筏过海
Cherish
皖公网安备34019202002308
